Fulgent Genetics (FLGT) Common Equity (2015 - 2026)

Fulgent Genetics has reported Common Equity for 12 years, with the latest figure at $1.0 billion in Q2 2026.

• Quarterly Common Equity fell 9.9% year-over-year to $1.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.0 billion (down 9.9% YoY) and the FY2025 annual result came in at $1.1 billion, down 1.52% from the prior year.
• Common Equity declined to $1.0 billion in Q2 2026 per FLGT's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Common Equity peaked at $1.3 billion in Q1 2022 and troughed at $1.0 billion in Q2 2026.
• A 5-year average of $1.2 billion and a median of $1.1 billion in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2024: Common Equity surged 63.8% in 2022, then fell 11.21% in 2024.
• Over 5 years, Common Equity stood at $1.3 billion in 2022, then dropped by 10.76% to $1.1 billion in 2023, then dropped by 0.36% to $1.1 billion in 2024, then slipped by 1.52% to $1.1 billion in 2025, then dropped by 9.93% to $1.0 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $1.0 billion, $1.0 billion, and $1.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.